Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (5824)	3/8/2002 12:33:46 AM
From: Londo	Read Replies (2) \| Respond to of 52153

who have no concept of comercial reality Competing products that are nearly as good as what Soltara claims (and probably is) can be made available with a visit to the doctor, or even over the counter (up here in Canada). If I recall correctly, the FDA advisory committee had all of those drugs delayed for whatever reasons. Commercial reality often conflicts with consumer protection - it's much easier to dump stuff out in the oceans and lakes than to spend some money to develop processes to clean it up. Soltara won't save lives. The drug was never meant to save lives. Is the marginal benefit of having Soltara on the market worth the marginal risk that it could create by being on the market? I really don't know the answers to that, but somebody at the FDA thought not. Right now, the best alternative is to have people use the other (of roughly equal efficacy) products, and they'll do fine. The result for us as a nation is a much more costly drug development process and over the long term fewer efficatious products. Three words: Barriers to entry. This works for the investor's advantage, and the consumer as well, since the FDA makes sure that there isn't a tragedy of the commons situation occurring when every company tries to peddle their snake oil on the markets. (No, I'm not referring to Soltara as "snake oil", but rather those products you'd see on 2:00am info-mercials to "enhance size and pleasure") Quite frankly, I'm in complete agreement with Cacaito's view of the FDA: They're doing their jobs. They should be run by scientists, not politicans. Makes biotech investing exciting, eh? Now the only question that we can be asking ourselves is: Is SEPR worth the buy at 19 bucks a piece? Can they get the data before they have to fork over their convertible debt principal?